Phase II Trial of Eribulin for Locally Advanced Refractory or Metastatic Salivary Gland Cancers

Trial Profile

Phase II Trial of Eribulin for Locally Advanced Refractory or Metastatic Salivary Gland Cancers

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Eribulin (Primary)
  • Indications Salivary gland cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Oct 2017 Planned End Date changed from 1 Sep 2017 to 1 Dec 2017.
    • 17 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Sep 2017.
    • 15 Nov 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top